Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells

Ju,Donghong; Xie,Youming

doi:10.3892/mmr.2014.2522

Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells

Authors:
- Donghong Ju
- Youming Xie
View Affiliations

Affiliations: Karmanos Cancer Institute, Department of Oncology and Pathology, Wayne State University School of Medicine, Detroit, MI 48201, USA
Published online on: August 28, 2014 https://doi.org/10.3892/mmr.2014.2522
Pages: 2609-2612

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The proteasome has become an important target for cancer therapy with the approval of bortezomib for the treatment of relapsed/refractory multiple myeloma (MM). However, numerous patients with MM do not respond to bortezomib and those responding initially often acquire resistance. Recent clinical studies have also demonstrated that bortezomib is also inefficacious in the treatment of other types of cancer. Therefore, it is imperative to develop novel approaches and agents for proteasome-targeting cancer therapy. In the present study, it was revealed that dyclonine, a major component of the cough droplets Sucrets, markedly enhances the cytotoxic effects of bortezomib and minimizes drug resistance in MM cells. It was demonstrated that a combination of bortezomib and dyclonine markedly induced apoptosis of MM cells. The present study suggests a novel therapeutic use of an over‑the‑counter medicine for the treatment of MM.

View Figures

View References

1	Varshavsky A: The ubiquitin system, an immense realm. Annu Rev Biochem. 81:167–176. 2012. View Article : Google Scholar : PubMed/NCBI
2	Schwartz AL and Ciechanover A: The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu Rev Med. 50:57–74. 1999. View Article : Google Scholar : PubMed/NCBI
3	Xie Y: Feedback regulation of proteasome gene expression and its implications in cancer therapy. Cancer Metastasis Rev. 29:687–693. 2010. View Article : Google Scholar : PubMed/NCBI
4	Micel LN, Tentler JJ, Smith PG and Eckhardt GS: Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. J Clin Oncol. 31:1231–1238. 2013. View Article : Google Scholar : PubMed/NCBI
5	Orlowski RZ and Kuhn DJ: Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res. 14:1649–1657. 2008. View Article : Google Scholar : PubMed/NCBI
6	Teicher BA, Ara G, Herbst R, Palombella VJ and Adams J: The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res. 5:2638–2645. 1999.PubMed/NCBI
7	Voorhees PM and Orlowski RZ: The proteasome and proteasome inhibitors in cancer therapy. Ann Rev Pharmacol Toxicol. 46:189–213. 2006. View Article : Google Scholar : PubMed/NCBI
8	Kumar A, Galeb S and Djulbegovic B: Treatment of patients with multiple myeloma: an overview of systematic reviews. Acta Haematol. 125:8–22. 2011. View Article : Google Scholar : PubMed/NCBI
9	Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
10	Dimri GP: What has senescence got to do with cancer? Cancer Cell. 7:505–512. 2005. View Article : Google Scholar : PubMed/NCBI
11	Mansilla S, Bataller M and Portugal J: Mitotic catastrophe as a consequence of chemotherapy. Anticancer Agents Med Chem. 6:589–602. 2006. View Article : Google Scholar : PubMed/NCBI
12	Pan X, Ye P, Yuan DS, et al: A DNA integrity network in the yeast Saccharomyces cerevisiae. Cell. 124:1069–1081. 2006. View Article : Google Scholar : PubMed/NCBI
13	Tong AH, Lesage G, Bader GD, et al: Global mapping of the yeast genetic interaction network. Science. 303:808–813. 2004. View Article : Google Scholar : PubMed/NCBI
14	Giaever G, Flaherty P, Kumm J, et al: Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc Natl Acad Sci USA. 101:793–798. 2004. View Article : Google Scholar : PubMed/NCBI
15	Ju D, Wang X and Xie Y: Dyclonine and alverine citrate enhance the cytotoxic effects of proteasome inhibitor MG132 on breast cancer cells. Intl J Mol Med. 23:205–209. 2009.PubMed/NCBI
16	Kuhn DJ, Chen Q, Voothees PM, et al: Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 110:3281–3290. 2007. View Article : Google Scholar
17	Xu H, Ju D, Jarois T and Xie Y: Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells. Breast Cancer Res Treat. 107:267–274. 2008. View Article : Google Scholar : PubMed/NCBI
18	Milano A, Iaffaioli RV and Caponigro F: The proteasome: a worthwhile target for the treatment of solid tumours? Eur J Cancer. 43:1125–1133. 2007. View Article : Google Scholar : PubMed/NCBI
19	Lees ND, Skaggs B, Kirsch DR and Bard M: Cloning of the late genes in the ergosterol biosynthetic pathway of Saccharomyces cerevisiae - a review. Lipids. 30:221–226. 1995. View Article : Google Scholar : PubMed/NCBI
20	Bennati AM, Castelli M, Fazia MA, et al: Sterol dependent regulation of human TM7SF2 gene expression: role of the encoded 3beta-hydroxysterol Delta14-reductase in human cholesterol biosynthesis. Biochim Biophys Acta. 1761:677–668. 2006. View Article : Google Scholar : PubMed/NCBI
21	Holmer L, Pezhman A and Worman HJ: The human lamin B receptor/sterol reductase multigene family. Genomics. 54:469–476. 1998. View Article : Google Scholar : PubMed/NCBI
22	Meusser B, Hirsch C, Jarosch E and Sommer T: ERAD: the long road to destruction. Nat Cell Biol. 7:766–772. 2005. View Article : Google Scholar : PubMed/NCBI
23	Goldstein JL, DeBose-Boyd RA and Brown MS: Protein sensors for membrane sterols. Cell. 124:35–46. 2006. View Article : Google Scholar : PubMed/NCBI